URGN (STOCKS)
UroGen Pharma Ltd. Ordinary Shares
$30.865000
+1.145000 (+3.85%)
Prev close: $29.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Elizabeth Barrett
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,504.04M
- Employees
- 253
- P/E (TTM)
- -11.20
- P/B (TTM)
- -12.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.47 | $-0.49 | +0.0222 | +4.51% |
|
Dec 2025 (Q4)
|
$-0.54 | $-0.51 | -0.0275 | -5.37% |
|
Sep 2025 (Q3)
|
$-0.69 | $-0.71 | +0.0164 | +2.32% |
|
Jun 2025 (Q2)
|
$-1.05 | $-0.85 | -0.1996 | -23.47% |
Financial Statements
| Revenues | $140.49M |
| Benefits Costs and Expenses | $278.80M |
| Cost Of Revenue | $14.26M |
| Costs And Expenses | $278.80M |
| Gross Profit | $126.24M |
| Nonoperating Income/Loss | -$903.00K |
| Operating Expenses | $234.45M |
| Selling, General, and Administrative Expenses | $171.62M |
| Research and Development | $62.83M |
| Operating Income/Loss | -$108.21M |
| Income/Loss From Continuing Operations After Tax | -$133.23M |
| Income/Loss From Continuing Operations Before Tax | -$138.31M |
| Income Tax Expense/Benefit | -$5.09M |
| Net Income/Loss | -$133.23M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$133.23M |
| Net Income/Loss Available To Common Stockholders, Basic | -$133.23M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.74 |
| Basic Average Shares | 146,353,753 |
| Assets | $253.69M |
| Current Assets | $237.46M |
| Cash | $140.30M |
| Inventory | $20.92M |
| Other Current Assets | $76.24M |
| Noncurrent Assets | $16.23M |
| Fixed Assets | $616.00K |
| Other Non-current Assets | $15.61M |
| Liabilities | $377.94M |
| Current Liabilities | $50.64M |
| Accounts Payable | $17.21M |
| Wages | $9.84M |
| Other Current Liabilities | $23.59M |
| Noncurrent Liabilities | $327.31M |
| Long-term Debt | $200.00M |
| Other Non-current Liabilities | $127.31M |
| Equity | -$124.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$124.25M |
| Liabilities And Equity | $253.69M |
| Net Cash Flow From Operating Activities | -$165.74M |
| Net Cash Flow From Operating Activities, Continuing | -$165.74M |
| Net Cash Flow From Investing Activities | $66.83M |
| Net Cash Flow From Investing Activities, Continuing | $66.83M |
| Net Cash Flow From Financing Activities | $105.09M |
| Net Cash Flow From Financing Activities, Continuing | $105.09M |
| Net Cash Flow | $6.19M |
| Net Cash Flow, Continuing | $6.19M |
| Comprehensive Income/Loss | -$133.23M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$133.23M |
| Other Comprehensive Income/Loss | -$133.23M |
| Other Comprehensive Income/Loss Attributable To Parent | -$6.00K |